June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
The work-related burden of dry eye disease
Author Affiliations & Notes
  • Jelle Vehof
    Ophthalmology, University Medical Center Groningen, Netherlands
    Ophthalmology, King's College London, United Kingdom
  • Mathias Kaurstad Morthen
    Ophthalmology, University Medical Center Groningen, Netherlands
    Medical Biochemistry, Oslo University Hospital, Norway
  • Morten Magno
    Ophthalmology, University Medical Center Groningen, Netherlands
    Medical Biochemistry, Oslo University Hospital, Norway
  • Tor Utheim
    Medical Biochemistry, Oslo University Hospital, Norway
    Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway
  • Christopher J Hammond
    Ophthalmology, King's College London, United Kingdom
    Twin Research & Genetic Epidemiology, King’s College London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Jelle Vehof Santen; Alcon; UrsaPharm; Tramedico; TheaPharma, Code C (Consultant/Contractor); Mathias Kaurstad Morthen None; Morten Magno None; Tor Utheim None; Christopher Hammond None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1543 – A0268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jelle Vehof, Mathias Kaurstad Morthen, Morten Magno, Tor Utheim, Christopher J Hammond; The work-related burden of dry eye disease. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1543 – A0268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the relationship between dry eye disease (DED) and work functioning, unemployment, absenteeism, and worry about job loss in a general population.

Methods : 89,215 subjects (18–96 years, 59.5% female) from the Dutch population-based Lifelines cohort were included. DED was assessed using the validated Women’s Health study (WHS) questionnaire (either a clinical diagnosis of dry eye or both dryness and irritation symptoms often or constantly present). Unemployment, absenteeism, and worry were assessed with single-item questions. Work functioning was assessed in 36,399 working participants using the validated work role functioning questionnaire (WRFQ) 2.0. The relationships between DED and work functioning, unemployment, absenteeism, and worry about job loss were assessed with logistic regression models, corrected for age, sex, body mass index (BMI), income, education, smoking, and 48 comorbidities associated with dry eye.

Results : 9.1% of participants were defined as having DED: 8.5% had a previous clinical diagnosis of dry eye and 1.9% had highly symptomatic dry eye. Participants with DED had impaired overall work functioning compared to those without DED (49.4% vs 41.1%, OR 1.24, 95% CI 1.14-1.35, P=0.002, corrected for everything). Absenteeism was only slightly increased in DED participants (OR 1.10, 95% CI 1.01-1.20, P=0.04). DED carried a similar risk of impaired work functioning as rheumatoid arthritis and COPD. For participants with highly symptomatic dry eye (often or constant symptoms) impaired work functioning was even higher (60.3%) and at the level of obstructive sleep apnea syndrome and depression. The impaired work functioning scores seen with increasing symptom load were greater for undiagnosed subjects than for diagnosed subjects (interaction term ‘clinical diagnosis * dry eye symptoms’ P=0.002). After correction for comorbidities, DED was not associated with unemployment (OR 1.07, 95% CI 0.94-1.21, P=0.32), but remained tied to increased worry about job loss (OR 1.23, 95% CI 1.10-1.36, P<0.0005).

Conclusions : In this large population-based study, DED was particularly linked to a substantially impaired work functioning, and less to unemployment and absenteeism. The impact of DED on work functioning is comparable to that of other severe chronic disorders, and undiagnosed subjects may be more affected. This highlights the importance of recognizing DED as a severe disorder and providing a diagnosis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×